A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

Hypercholesterolemia Clinical Trial

Official title:

A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Statin Intolerant Hypercholesterolemia-

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05923281
• Other study ID #: K-877-ER-04
• Status: Recruiting
• Phase: Phase 3
• Start date: May 1, 2023
• Est. completion date: October 31, 2024

Study information

• Verified date: June 2023
• Source: Kowa Company, Ltd.
• Contact: Saito Ayumi
• Phone: 81-3-3279-7454
• Email: ctrdinfo[@]kowa.co.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the efficacy and safety of K-877 Extended Release 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with Statin Intolerant* Hypercholesterolemia,using placebo as a controll.

*Statin Intolerant: Adverse events associated with statin use that cause unacceptable disturbances in the user's daily life, resulting in drug discontinuation or dose reduction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: October 31, 2024
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: The person who meet all the following criteria the object to the clinical trial

1. Patients had to be age 18 years or older at written informed consent

2. Patients with statin intolerant hypercholesterolemia

3. Patients who have laboratory records with fasting serum TG <= 150 mg/dL (<=175 mg/dL when not fasting) within 6 months prior to consent.

4. Patients with the fasting serum TG <= 150 mg/dL at screening

5. Patients who have received dietary or exercise guidance from 12 weeks or more prior to Screening

6. Patients who apply any of the following risk category with LDL-C level (Friedewald formula) based on JAS2022 at screening

• Low risk for primary prevention: LDL-C >=160 mg/dL

• Intermediate risk for primary prevention: LDL-C >=140 mg/dL

• High risk for primary prevention: LDL-C>=120 mg/dL

• Secondary prevention: LDL-C>=120 mg/dL

Exclusion Criteria: The person who meet any of the following criteria will be excluded from the study.

1. Patients who require administration of prohibited drugs during the clinical trial period after written informed consent

2. Patients with type 1 diabetes and uncontrolled diabetes [HbA1c(NGSP) >= 10.0 % at Screening]

3. Patients with uncontrolled thyroid disease

4. Patients with undergoing LDL apheresis

5. Patients with cirrhosis or those with biliary obstruction

6. Patients with familial hypercholesterolemia (homozygotes)

7. Patients with uncontrolled hypertension (SBP >= 160 mmHg or DBP >= 100 mmHg) at Screening

8. Patients with an AST or ALT three times the upper limit at Screening

9. Patients with an CK four times the upper limit at Screening

10. Patients with any of the following criteria within 3 months before obtaining informed consent: myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass surgery, stroke, transient ischemic attack, symptomatic carotid artery stenosis, symptomatic peripheral arterial disease, abdominal aortic aneurysm, uncontrolled severe arrhythmia and decompensated heart failure

11. Patients who plan to undergo PCI, CABG, carotid artery or peripheral revascularization

12. Patients with heart failure class III or higher according to NYHA cardiac function classification

13. Patients with malignant tumor or those who are judged to have a high risk of recurrence

14. Patients with a history of myopathy or rhabdomyolysis due to K-877 (pemafibrate)

15. Patients with a history of hypersensitivity due to K-877 (pemafibrate)

16. Patients with a history of serious drug allergies (anaphylactic shock, etc.)

17. Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women*2 who do not use specific contraceptive methods*1

18. Patients who have collected 400 mL or more of whole blood within 16 weeks, or 200 mL or more of whole blood within 4 weeks, or blood samples (plasma and platelet components) within 2 weeks before Screening

19. Patients with alcoholics or drug addicts

20. Patients who participated in other clinical trials of a drug with new active ingredients within 16 weeks or a drug with an approved active ingredients within 12 weeks prior to administration and received an investigational drug other than placebo,or those who will participate in other clinical trials at the same time as the clinical trial

21. Patients who have been determined inappropriate by the investigator, etc

• 1 Acceptable contraceptive methods: oral, implantable/injectable contraceptive hormones, mechanical products [intrauterine devices (IUDs) ,etc] or barrier methods with spermicides (pessaries, condoms, cervical caps, etc)

• 2 Woman of childbearing potential refers to a woman who is physiologically capable of becoming pregnant with a male partner who has not undergone contraception. However, it does not apply if the investigator confirms that any of the following criteria is met.

• Patients with hysterectomy or tubal ligation before informed consent

• Post-menopausal women (those who who have passed more than 1 year since their last menstrual period without other medical reasons).

Related Conditions & MeSH terms

• Hypercholesterolemia

Intervention

Drug:
• K-877 0.2 mg/day (once daily)
K-877 0.2mg tablet
• K-877 0.4 mg/day (once daily)
K-877 0.2mg tablet
• Placebo (once daily)
Placebo tablet

Locations

Country	Name	City	State
Japan	Nakayama Clinic	Aichi
Japan	Kohnodai Hospital, National Center for Global Health and Medicine	Chiba
Japan	Tashiro Endocrinology Clinic	Fukuoka
Japan	NTT Medical Center Sapporo	Hokkaido
Japan	Tsukuba Medical Center Foundation Tsukuba Medical Center Hospital	Ibaraki
Japan	Yokohama Minami Kyosai Hospital	Kanagawa
Japan	Medical Corporation LONGWOOD Maeda Clinic	Osaka
Japan	OCROM Clinic	Osaka
Japan	Rinku General Medical Center	Osaka
Japan	Koshigaya Municipal Hospital	Saitama
Japan	Saitama Medical University Hospital	Saitama
Japan	Affiliated CENTRAL CLINIC of Higashiyamato Hospital	Tokyo
Japan	Medical Corporation Chiseikai Tokyo Center Clinic	Tokyo
Japan	Mishuku Hospital	Tokyo
Japan	ToCROM Clinic	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Kowa Company, Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change from baseline in LDL-C (formula F).	Percent change = (measured value at each time point - baseline value) / baseline value	4, 8, and 12 weeks after administration
Secondary	Efficacy: % change from baseline in fasting serum LDL-C (mg/dL)(Direct)		4, 8, and 12 week after administration
Secondary	Efficacy: % change from baseline in fasting serum HDL-C (mg/dL)		4, 8, and 12 week after administration
Secondary	Efficacy: % change from baseline in fasting serum non HDL-C (mg/dL)		4, 8, and 12 week after administration
Secondary	Efficacy: % change from baseline in fasting serum TG (mg/dL)		4, 8, and 12 week after administration
Secondary	Efficacy: % change from baseline in fasting serum LDL-C(formula F)/HDL-C		4, 8, and 12 week after administration
Secondary	Efficacy: % change from baseline in fasting serum non HDL-C/HDL-C		4, 8, and 12 week after administration